Effective September 15, 2025: Clinical Policies
Date: 07/16/25
Superior HealthPlan has updated certain clinical policies to ensure medical necessity review criteria is current and appropriate for members and the scope of services provided. As a result the following policies are effective on September 15, 2025, at 12:00AM.
POLICY | APPLICABLE PRODUCTS | NEW POLICY OVERVIEW OR UPDATED POLICY REVISIONS |
Allogeneic Hematopoietic Progenitor Cell Therapy (CP.MP.249) | Ambetter | Policy updates include:
|
Fecal Incontinence Treatments (CP.MP.137) | Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP, and Ambetter | Policy updates include:
|
Reduction Mammoplasty and Gynecomastia Surgery (CP.MP.51) | Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP, and Ambetter | Policy updates include:
|
Skin and Soft Tissue Substitutes for Chronic Wounds (CP.MP.185) | Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP, and Ambetter | Policy updates include:
|
To review all policies, please visit Superior’s Clinical, Payment & Pharmacy Policies webpage.
Prior to updates, Medical Clinical policies are reviewed and approved by the Utilization Management Committee.
For questions or additional information, contact Superior’s Prior Authorization department at 1-800-218-7508.